JUBLPHARMA

Jubilant Pharmova Limited

Diversified pharmaceutical group with radiopharmaceuticals, allergy immunotherapy and CRDMO business

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

jubilantpharmova.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹938.60
Market cap
14,855 Cr
Stock P/E
42.2
P/B
2.09
Dividend yield
0.5%
ROE (FY26)
5.6%
ROCE (FY26)
8.0%
Operating margin (FY26)
9.9%
Debt / equity (FY26)
0.45
OCF / EBITDA (FY26)
97.4%
OCF / EBITDA (3Y)
98.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Jubilant Pharmova makes radiopharmaceuticals, allergy immunotherapy products, generic medicines and APIs, and provides contract development and manufacturing services, mostly to customers in the US.

Company snapshot

37thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-12-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 46.2% of revenue

SegmentRevenue shareRevenuePBTAssets
Allergy Immunotherapy
9.6%
174 Cr47 Cr482 Cr
Contract Dev. and Manf. Org.-Sterile Injectables
17.4%
316 Cr33 Cr4,155 Cr
Contract Research, Dev. and Manufacturing Organisation
16.4%
299 Cr35 Cr1,574 Cr
Generics
11.0%
200 Cr19 Cr1,231 Cr
Proprietary Novel Drugs—0 Cr-5 Cr262 Cr
Radiopharma
46.2%
841 Cr95 Cr3,014 Cr
Unallocable Corporate
0.6%
11 Cr0 Cr1,428 Cr

Shares add up to 101% because segment revenues are before inter-segment eliminations.

What we see

Positives
  • ✓98% of operating profit came in as cash over the last three years — profits are backed by real cash.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,680 Cr1,677 Cr1,759 Cr1,732 Cr1,752 Cr1,822 Cr1,929 Cr1,901 Cr1,966 Cr2,123 Cr2,290 Cr2,229 Cr
Operating expenses (approx.)1,439 Cr1,459 Cr1,487 Cr1,480 Cr1,463 Cr1,534 Cr1,583 Cr1,611 Cr1,625 Cr1,833 Cr1,951 Cr1,981 Cr
EBITDA242 Cr218 Cr271 Cr252 Cr289 Cr287 Cr345 Cr290 Cr341 Cr290 Cr339 Cr248 Cr
OPM %14.4%13.0%15.4%14.5%16.5%15.8%17.9%15.2%17.4%13.6%14.8%11.1%
Other income10 Cr36 Cr14 Cr14 Cr22 Cr9 Cr12 Cr12 Cr10 Cr21 Cr24 Cr20 Cr
Interest66 Cr71 Cr73 Cr71 Cr61 Cr56 Cr53 Cr49 Cr50 Cr56 Cr57 Cr54 Cr
Depreciation97 Cr95 Cr101 Cr91 Cr91 Cr91 Cr95 Cr98 Cr105 Cr121 Cr117 Cr127 Cr
Profit before tax98 Cr101 Cr-54 Cr500 Cr144 Cr131 Cr206 Cr154 Cr190 Cr93 Cr176 Cr86 Cr
Tax %36.6%34.3%-15.1%3.6%29.0%22.8%26.6%33.6%37.0%40.3%32.2%34.7%
Net profit62 Cr66 Cr-62 Cr482 Cr103 Cr101 Cr151 Cr103 Cr120 Cr56 Cr119 Cr56 Cr
EPS (₹)₹3.94₹4.22₹-3.69₹30.44₹6.47₹6.37₹9.71₹6.49₹7.59₹3.52₹7.55₹3.57

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6,006 Cr7,465 Cr9,111 Cr9,154 Cr6,099 Cr6,059 Cr6,282 Cr6,703 Cr7,235 Cr8,280 CrSign in free for the trailing twelve months
Operating expenses (approx.)4,661 Cr6,039 Cr7,372 Cr7,207 Cr4,702 Cr4,974 Cr5,505 Cr5,802 Cr6,061 Cr7,020 CrSign in free for the trailing twelve months
EBITDA1,345 Cr1,425 Cr1,739 Cr1,947 Cr1,396 Cr1,085 Cr776 Cr901 Cr1,174 Cr1,260 CrSign in free for the trailing twelve months
OPM %22.4%19.1%19.1%21.3%22.9%17.9%12.4%13.4%16.2%15.2%Sign in free for the trailing twelve months
Other income25 Cr133 Cr36 Cr47 Cr18 Cr82 Cr38 Cr69 Cr57 Cr66 CrSign in free for the trailing twelve months
Interest341 Cr284 Cr220 Cr287 Cr184 Cr145 Cr188 Cr272 Cr240 Cr212 CrSign in free for the trailing twelve months
Depreciation291 Cr415 Cr371 Cr462 Cr349 Cr382 Cr554 Cr382 Cr369 Cr440 CrSign in free for the trailing twelve months
Profit before tax738 Cr859 Cr904 Cr1,211 Cr1,212 Cr630 Cr28 Cr171 Cr981 Cr614 CrSign in free for the trailing twelve months
Tax %22.1%26.2%36.2%25.8%31.1%34.5%333.5%57.4%14.7%35.3%Sign in free for the trailing twelve months
Net profit575 Cr634 Cr577 Cr898 Cr836 Cr413 Cr-65 Cr73 Cr836 Cr398 CrSign in free for the trailing twelve months
EPS (₹)₹36.93₹41.25₹36.86₹56.39₹52.48₹26.00₹-3.83₹4.87₹52.99₹25.15Sign in free for the trailing twelve months
Dividend payout %————-0.2%19.4%—109.8%9.5%20.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr
Reserves3,420 Cr4,071 Cr4,793 Cr5,588 Cr4,726 Cr5,303 Cr5,383 Cr5,418 Cr6,239 Cr7,077 Cr
Borrowings3,761 Cr3,293 Cr4,743 Cr4,390 Cr2,584 Cr2,928 Cr3,410 Cr3,414 Cr2,437 Cr3,220 Cr
Other liabilities1,891 Cr2,290 Cr1,917 Cr2,528 Cr1,593 Cr1,747 Cr2,355 Cr2,713 Cr4,081 Cr5,208 Cr
Total liabilities9,041 Cr9,618 Cr11,469 Cr12,522 Cr8,918 Cr9,991 Cr11,157 Cr11,549 Cr12,756 Cr15,523 Cr
Fixed assets (net)3,104 Cr3,193 Cr3,396 Cr3,751 Cr2,008 Cr2,201 Cr2,298 Cr2,158 Cr2,132 Cr3,510 Cr
CWIP211 Cr300 Cr492 Cr264 Cr278 Cr292 Cr773 Cr1,252 Cr2,715 Cr2,962 Cr
Investments103 Cr124 Cr115 Cr69 Cr241 Cr239 Cr256 Cr42 Cr44 Cr61 Cr
Loans & advances——4 Cr3 Cr1 Cr1 Cr1 Cr0.80 Cr1 Cr2 Cr
Inventories1,220 Cr1,391 Cr1,417 Cr1,845 Cr1,129 Cr1,255 Cr1,381 Cr1,290 Cr1,129 Cr1,232 Cr
Trade receivables1,005 Cr1,131 Cr1,272 Cr1,293 Cr820 Cr928 Cr961 Cr916 Cr892 Cr1,070 Cr
Cash & bank456 Cr244 Cr1,005 Cr1,231 Cr502 Cr984 Cr1,014 Cr956 Cr1,088 Cr1,267 Cr
Other assets2,941 Cr3,235 Cr3,768 Cr4,065 Cr3,939 Cr4,091 Cr4,473 Cr4,934 Cr4,756 Cr5,420 Cr
Total assets9,041 Cr9,618 Cr11,469 Cr12,522 Cr8,918 Cr9,991 Cr11,157 Cr11,549 Cr12,756 Cr15,523 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity1,268 Cr1,303 Cr1,122 Cr1,543 Cr1,482 Cr838 Cr661 Cr971 Cr1,072 Cr1,227 Cr
Cash from investing-450 Cr-618 Cr-1,012 Cr-327 Cr721 Cr-380 Cr-544 Cr-608 Cr488 Cr-1,260 Cr
Cash from financing-686 Cr-901 Cr657 Cr-1,050 Cr3,453 Cr-33 Cr-157 Cr-432 Cr-1,453 Cr95 Cr
Net cash flow117 Cr-212 Cr761 Cr225 Cr5,656 Cr482 Cr30 Cr-57 Cr132 Cr179 Cr
Free cash flow (OCF − Capex)804 Cr814 Cr466 Cr969 Cr1,482 Cr238 Cr-154 Cr74 Cr-43 Cr-222 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %15.1%15.6%11.8%15.0%19.1%9.4%2.5%5.0%14.1%8.0%
ROE %17.0%15.7%11.9%16.0%17.6%7.8%-1.1%1.4%13.5%5.6%
Debtor days61555152495656504547
Inventory days230189157216305339302258207193
Days payable141154113128140153179172184194
Cash conversion cycle15090951402132411781376847
OCF / EBITDA %94.3%91.4%64.5%79.2%106.2%77.2%85.1%107.8%91.3%97.4%
OCF / EBITDA % (3 years)——81.9%77.6%81.6%87.2%91.5%89.4%94.9%98.1%
Debt / equity1.110.820.990.780.540.550.630.630.390.45
Current ratio1.751.592.191.922.822.202.121.921.621.62
Net debt / EBITDA2.46—2.151.621.491.793.092.731.151.55